Alexa C. Cannon

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “RAC1 as a Therapeutic Target in Malignant Melanoma”.

RAC1 as a Therapeutic Target in Malignant Melanoma

Trends in cancer(2020)10.1016/j.trecan.2020.02.021

N/A

0DataRank · unranked

66 citations

Cristina Uribe‐Alvarez, Jonathan Chernoff, Alexa C. Cannon

Unique vulnerability of RAC1 -mutant melanoma to combined inhibition of CDK9 and immune checkpoints

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.27.546707

N/A

0DataRank · unranked

2 citations

Konstantin Budagyan, Cristina Uribe‐Alvarez, Alison Kurimchak, Daniela Araiza‐Olivera, Kathy Q. Cai +5 more

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

Research Square(2023)10.21203/rs.3.rs-3160616/v1

N/A

0DataRank · unranked

1 citations

Alexa C. Cannon, Konstantin Budagyan, Cristina Uribe‐Alvarez, Alison Kurimchak, Daniela Araiza‐Olivera +5 more

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

Oncogene(2024)10.1038/s41388-024-02947-z

N/A

0DataRank · unranked

12 citations

Konstantin Budagyan, Cristina Uribe‐Alvarez, Alison Kurimchak, Daniela Araiza‐Olivera, Kathy Q. Cai +5 more

KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation

Cell Reports(2025)10.1016/j.celrep.2025.115444

N/A

0DataRank · unranked

6 citations

Alexa C. Cannon, Adam Chatoff, Dorothy Benton, Alison Kurimchak, Daniela Araiza‐Olivera +6 more